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ABSTRACT
CONTEXT AND OBJECTIVES: Effective postoperative analgesia is important for reducing the incidence of 
chronic pain. This study evaluated the effect of preoperative gabapentin on postoperative analgesia and 
the incidence of chronic pain among patients undergoing carpal tunnel syndrome surgical treatment.
DESIGN AND SETTINGS: Randomized, double-blind controlled trial, Federal University of São Paulo 
Pain Clinic.
METHODS: Forty patients aged 18 years or over were randomized into two groups: Gabapentin Group 
received 600 mg of gabapentin preoperatively, one hour prior to surgery, and Control Group received 
placebo. All the patients received intravenous regional anesthesia comprising 1% lidocaine. Midazolam 
was used for sedation if needed. Paracetamol was administered for postoperative analgesia as needed. 
Codeine was used additionally if the paracetamol was insufficient. The following were evaluated: postop-
erative pain intensity (over a six-month period), incidence of postoperative neuropathic pain (over a six-
month period), need for intraoperative sedation, and use of postoperative paracetamol and codeine. The 
presence of neuropathic pain was established using the DN4 (Douleur Neuropathique 4) questionnaire. 
Complex regional pain syndrome was diagnosed using the Budapest questionnaire.
RESULTS: No differences in the need for sedation, control over postoperative pain or incidence of chron-
ic pain syndromes (neuropathic or complex regional pain syndrome) were observed. No differences in 
postoperative paracetamol and codeine consumption were observed. 
CONCLUSIONS: Preoperative gabapentin (600 mg) did not improve postoperative pain control, and did 
not reduce the incidence of chronic pain among patients undergoing carpal tunnel syndrome surgery.
RESUMO
CONTEXTO E OBJETIVOS: Analgesia pós-operatória eficaz é importante para reduzir a incidência de dor 
crônica. Este estudo avaliou o efeito da gabapentina pré-operatória na analgesia pós-operatória e na inci-
dência de dor crônica em pacientes submetidos à cirurgia para tratamento da síndrome do túnel do carpo.
DESENHO E LOCAL: Randomizado, duplo cego, Universidade Federal de São Paulo.
MÉTODOS: Os 40 pacientes com 18 anos ou mais de idade foram distribuídos aleatoriamente em dois 
grupos: o Grupo Gabapentina recebeu 600 mg de gabapentina no pré-operatório uma hora antes da ci-
rurgia, e o Grupo Controle recebeu placebo. Todos os pacientes receberam anestesia regional intravenosa 
com lidocaína a 1%. Midazolam foi utilizado para sedação, se necessário. Paracetamol foi administrado para 
analgesia pós-operatória, conforme necessário, e codeína, se o paracetamol fosse insuficiente. Foram ava-
liados: a intensidade da dor pós-operatória (durante seis meses), a incidência de dor neuropática pós-ope-
ratória (durante seis meses), a necessidade de sedação intra-operatória e o uso de paracetamol e codeína 
no pós-operatório. A presença de dor neuropática foi estabelecida utilizando-se o questionário DN4 (dor 
neuropática 4). Síndrome de dor regional complexa foi diagnosticada através do questionário Budapeste.
RESULTADOS: Não foram observadas diferenças na necessidade de sedação, no controle da dor pós-ope-
ratória e na incidência de síndromes dolorosas crônicas (neuropáticas ou síndrome de dor regional com-
plexa). Não foram observadas diferenças no consumo de paracetamol e codeína.
CONCLUSÕES: Gabapentina pré-operatória (600 mg) não melhorou o controle da dor pós-operatória e 
não reduziu a incidência de dor crônica em pacientes submetidos à cirurgia para tratamento da síndrome 
do túnel do carpo.
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INTRODUCTION
Carpal tunnel syndrome surgery is usually a short outpatient 
procedure performed under intravenous regional anesthesia 
(IVRA). However, this type of anesthesia is unable to maintain 
postoperative analgesia.1,2
Many patients will develop chronic pain after hand sur-
gery, especially complex regional pain syndrome, which is asso-
ciated with neuropathic, inflammatory and sympathetic dysfunc-
tion mechanisms.3,4 Postoperative chronic pain (POCP) has been 
observed in more than 20% of patients after carpal tunnel release.1,5
The occurrence of postoperative acute pain is an important 
predictor for the development of chronic pain. Adequate analge-
sia in the acute postoperative phase reduces the risk of chronic 
pain. Effective postoperative analgesia is of major importance for 
preventing POCP.6,7
Gabapentin is known to reduce dorsal horn neuron excit-
ability and central sensitization through various mechanisms.8-10 
A review of the literature suggested that the incidence of postop-
erative chronic pain was reduced through using gabapentin peri-
operatively.11 However, a study on a single preoperative 300  or 
600 mg dose of gabapentin prior to caesarean section did not 
show any improvement in pain control.12 Therefore, the role of 
preoperative gabapentin for postoperative pain control remains 
a matter of controversy. 
This study evaluated the effect of preoperative gabapentin on 
postoperative pain control and chronic pain incidence among 
patients undergoing carpal tunnel syndrome surgery under 
IVRA. The primary objective was to evaluate the effect of preop-
erative gabapentin on postoperative pain control. The secondary 
objectives were to investigate the incidence of chronic pain, and 
the adverse event profile of gabapentin and lidocaine.
METHODS
Ethics approval for this study was provided by the Ethics Committee 
of the Federal University of São Paulo under the number 0223/09. 
The trial was registered at ClinicalTrials.gov (NCT01632215).
Study design
This was a prospective, randomized, double-blind study. 
Place and setting
All patients underwent surgery performed using the same tech-
nique (open carpal tunnel release surgery), by the same medi-
cal team at the hospital of the Federal University of São Paulo 
between 2009 and 2011.
Participants
The inclusion criteria were that the patients needed to be 18 years 
of age or older, of either gender, and presenting American Society 
of Anesthesia (ASA) physical status I or II, before open carpal tun-
nel release surgery. Carpal tunnel syndrome needed to have been 
diagnosed by means of clinical examinations (Phalen and Tinel 
tests) and electromyography (grade ≥ 2). The electromyography 
scale was graded as follows: normal (grade 0); very mild (grade 1), 
carpal tunnel syndrome demonstrable only with the most sensi-
tive tests; mild (grade 2), sensory nerve conduction velocity slow 
on finger/wrist measurement, and normal terminal motor latency; 
moderate (grade 3), sensory potential preserved with motor slow-
ing, and distal motor latency to abductor pollicis brevis (APB) 
< 6.5  ms; severe (grade 4), sensory potential absent but motor 
response preserved, and distal motor latency to APB < 6.5 ms; very 
severe (grade 5), terminal latency to APB > 6.5 ms; and extremely 
severe (grade 6), sensory and motor potentials effectively unrecord-
able (surface motor potential from APB < 0.2 mV in amplitude).13
Patients presenting arrhythmia, myocardial ischemia, cogni-
tive impairment, psychiatric disorders, drug abuse, pregnancy, 
sensitiveness to anesthetics or opioid, anticonvulsant or antide-
pressant use were excluded. 
The sample size was calculated using SPSS 17 for Windows. 
A reduction of approximately two points or 30% in the numeri-
cal rating scale14 for pain intensity represented a clinically impor-
tant difference in chronic pain.15 To optimize the relevance of 
the study findings, a three-point difference in a numerical pain 
intensity score was chosen to be a clinically meaningful endpoint. 
For a power of 95% (beta), an alpha level of 5% and an estimated 
standard deviation of the population of 2.44, based on a prelimi-
nary evaluation,16 the calculated sample size was 18 patients per 
group to demonstrate a three-point difference in the scores. 
Randomization, allocation concealment and blinding
The patients were randomly assigned to one of two paral-
lel groups in a 1:1 ratio, through using the computer program 
Randomizer. Opaque envelopes were prepared in accordance 
with the computer randomization and were numbered and sealed 
by a researcher who was not involved in patient assessment. Each 
envelope contained either a gabapentin or a placebo tablet and 
was stored at the research hospital, to be given to the research 
physician prior to each surgery. The gabapentin and placebo tab-
lets were identical in order to maintain patients and researchers 
blinded to the randomization group. None of the participating 
physicians or the researchers involved in data collection were 
aware of the patient study-group randomization. Patients ran-
domized to the Gabapentin Group received 600 mg of gabapen-
tin 1 hour prior to surgery. Patients randomized to the Control 
Group received placebo. 
All patients were asked about dizziness symptoms prior 
to the onset of anesthesia, and were subsequently assessed for 
behavioral changes.
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Preoperative and operative procedures
Anesthesia, surgical procedure and patient follow-up were per-
formed by the same research physicians for all patients. Routine 
monitoring by means of electrocardiogram (ECG), pulse oxim-
etry and noninvasive blood pressure (NIBP) was conducted 
throughout the duration of patient anesthesia. IVRA was per-
formed with 20 ml of 1% lidocaine, using two tourniquets, in 
accordance with the technique described by Bier.2 In cases of 
persistent pain after IVRA, local infiltration of 1% lidocaine was 
performed and the total dose used was recorded. Midazolam was 
administered for sedation if needed, e.g. if the patient became 
agitated, and the total dose was recorded. 
Paracetamol (maximum of 4 g/24 h) was given if postsurgi-
cal analgesia was required, for up to 6 months post-surgery, e.g. if 
patients reported moderate or severe pain, defined as a numerical 
scale score ≥ 4 (on a scale ranging from 1 to 10). Codeine (30 mg) 
was given if paracetamol was insufficient for pain control. The 
use of other drugs was not allowed for pain control during the 
follow-up period. The use of specific orthosis was not allowed 
prior to or after the procedure.
Outcomes (primary and secondary)
The primary outcome was pain intensity according to a numeri-
cal scale (0 = no pain, 10 = worst pain possible) prior to procedure 
(T-preoperative), at time 0 min (T0 = time of tourniquet release), 
30 min, 1 h, 2 h, 2 weeks, 1 month, 3 months and 6 months after 
the procedure. Secondary outcomes included: total dose of lido-
caine supplementation; need for and dose of midazolam; post-
operative need for and total dose of paracetamol and/or codeine; 
development of neuropathic pain and/or complex regional pain 
syndrome. The DN4 (Douleur Neuropathique 4) questionnaire,6 
which evaluates seven sensory symptoms and three signs on 
physical exam, indicated neuropathic pain for patients with a 
score ≥ 4, measured at different assessment points (before anes-
thesia and at 2 weeks, 1 month, 3 months and 6 months after 
surgery). Complex regional pain syndrome was diagnosed 
using the Budapest questionnaire15 on scheduled assessment 
dates (2 weeks, 1 month, 3 months and 6 months after surgery). 
Possible side effects were recorded. 
Statistical analysis
SPSS 17 for Windows was used for the statistical analysis. 
Parametric variables were expressed as means ± standard devi-
ation (SD). Nonparametric variables were described as median, 
25th and 75th percentile values. The Mann-Whitney test was used 
to analyze age, weight, height and body mass index (BMI). The 
Chi-square test was applied to gender and pain scores. For pain 
intensity analysis, patients were grouped according to pain inten-
sity score at the different assessment points: mild (score < 4) or 
moderate/severe pain intensity (score ≥ 4). Proportion tests were 
used to assess pain intensity score groups between the assess-
ment times (T-preoperative compared with other study points). 
The McNemar test was used for comparisons within the same 
study groups. The Mantel-Haenszel test was used for compari-
sons between study groups. Student’s t test was used to analyze 
total paracetamol and midazolam doses, anesthesia and surgery 
duration, and occurrences of complex regional pain syndrome. 
Fisher’s test was used to evaluate occurrences of neuropathic 
pain and adverse effects, and the patients’ baseline character-
istics (diabetes and prior treatment for carpal tunnel disease). 
The  likelihood test was used to evaluate the electromyography 
grade of the carpal tunnel syndrome. Missing data were excluded 
from the analysis.
RESULTS
The patients’ recruitment and allocation flowchart, according to 
the CONSORT guideline, is shown in Figure 1. Twenty patients 
were excluded from the study: two due to arrhythmia, four due 
to myocardial ischemia and 14 due to opioid, anticonvulsant or 
antidepressant use. A total of 40 patients were included in the 
study, i.e. 20 in each group.
There were no differences in patient demographics, duration 
of surgery and anesthesia, need for midazolam use, carpal tun-
nel syndrome grade or previous diabetic status between the study 
groups (Table 1). Lidocaine supplementation was not required 
for any patient. All the patients were ASA I or II, with no differ-
ence between the groups (P = 0.642). All the patients were female. 
Table 1. Demographic data of patients with carpal 
tunnel syndrome
Gabapentin (n = 20) Control (n = 20) P
Age (years) 51.5 (48.5-54) 52.1 (46-56.7) 0.583*
Weight (kg) 65.7 (59.2-73) 68.7 (60-75) 0.383*
Height (cm) 158 (155-161.5) 157 (154-162) 0.939*
BMI (kg/m2)  26.2 (23.6-28.7) 27.5 (23.9-31.4) 0.659*
Duration of 
surgery
33.06 ± 10.86 min 33.06 ± 16.90 min 0.894†
Duration of 
anesthesia
55.00 ± 11.50 min 54.21 ± 11.33 min 0.835†
Need for 
midazolam
7/18 5/19 0.823†
Grade of carpal syndrome
Grade 2 1 2
0.93‡
Grade 3 7 8
Grade 4 10 10
Grade 5 1 1
Diabetes 2/18 1/19 1.00§
Treatment 
naive
18/18 19/19 1.00§
BMI = body mass index. *Mann-Whitney test [median (25th and 75th 
percentiles)]; †Student’s t test (mean ± SD); ‡likelihood test; §Fisher test.
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The postoperative assessments showed lower pain intensity 
scores in comparison with the preoperative baseline pain inten-
sity within the same study groups, except for the T30 min assess-
ment (McNemar’s test, Table 2). However, there was no statisti-
cally significant difference in pain intensity scores over time in 
comparisons across study groups (Mantel-Haenszel test, Table 2). 
There was no statistically significant difference in the incidence 
of chronic neuropathic pain (Table 3) or complex regional pain 
syndrome between the study groups (Table 4). 
There was no difference in the use of paracetamol 
(Gabapentin Group: 24.6 ± 30.1 doses; 95% CI: 13.1 ± 48.1; and 
Control Group: 30.9 ± 36.9 doses; 95% CI: 9.6 - 39.5; P = 0.572; 
Student’s t test) or codeine supplementation (Gabapentin Group: 
0; Control Group: 1) over the six-month observation period 
between the study groups. 
The adverse effects were similar at the preoperative assessment 
(beginning of surgery): metallic taste: 4 versus 2 (P = 0.660); oral 
paresthesia: 2 versus 1 (P = 1.0); dizziness: 4 versus 4 (P = 1.0); som-
nolence: 4 versus 3 (P = 1.0); and tinnitus 2 versus 4 (P = 0.660); for 
the Gabapentin and Control groups, respectively. No differences in 
adverse effects at the end of surgery were noted: metallic taste: 0 
versus 1 (P = 1.0); oral paresthesia: 0 versus 0; dizziness: 3 versus 1 
(P = 0.605); drowsiness: 2 versus 0 (P = 0.487); and tinnitus: 2 versus 
0 (P = 0.486); for the Gabapentin and Control groups, respectively.
DISCUSSION
The current study did not demonstrate any difference in pain 
intensity scores, incidence of postoperative chronic pain (POCP) 
or complex regional pain syndrome (CRPS), need for addi-
tional postoperative analgesia or incidence of adverse effects, 
through using preoperative gabapentin for open carpal tunnel 
release surgery.
The demographic data were similar between the study 
groups. Interestingly, only female patients were included, despite 
no exclusion of male patients. This could be explained by the 
known higher prevalence of carpal tunnel syndrome in women.5 
Previous studies have shown that there is a reduced risk of 
POCP after other types of surgery with the use of gabapentin pre-
operatively.17-19 In the current report, the observed incidence of 
POCP and CRPS was lower for the gabapentin group, but it did 
not reach statistical significance, despite a numerical difference.
Gabapentin was administered one hour prior to surgery to allow 
for drug absorption.20 The use of a single 600 mg dose of gabapentin 
could explain the lack of efficacy observed. Pre and postoperative 
gabapentin administration could have prevented central sensitiza-
tion from previous pain stimulus, surgical trauma and postopera-
tive inflammation, and may have influenced the outcomes.
However, the use of 600 mg of gabapentin preoperatively fol-
lowed by two-day maintenance had no beneficial effect after total 
knee arthroplasty.21 Also, two study reviews were unable to dem-
onstrate that preoperative gabapentin was effective for prevention 
of postoperative chronic pain,22 even at a higher dose (1200 mg).23 
However, it should be noted that there was a difference in surgical 
trauma between those studies and the current report. 
A study by Pandey et al.24 demonstrated that there was lower 
opioid consumption and reduced pain scores through using a single 
Table 2. Intensity of pain (pain ≥ 4/pain < 4) among patients operated for carpal tunnel syndrome
Time points Gabapentin (n = 18)
McNemar’s test 
(Gabapentin Group)*
Control (n = 19)
McNemar’s test 
(Control Group)*
Chi-square Mantel-Haenszel test*
Preoperative 17/1 18/1 0.969
T0 1/17 0.000 1/18 0.000 0.969 0.221
30 minutes 15/3 0.625 18/1 1.00 0.264 0.518
1 hour 4/14 0.01 8/11 0.02 0.197 0.824
2 hours 0/18 n/a 0/19 n/a n/a n/a
2 weeks 9/9 0.012 12/7 0.05 0.634 0.596
1 month 8/10 0.012 11/8 0.039 0.413 0.496
3 months 4/14 0.001 4/15 0.001 0.931 0.067
6 months 3/15 0.000 2/17 0.000 0.948 0.637
T0 = time of tourniquet release; n/a = not applicable; * = P-values.
Table 3. Neuropathic pain (DN4 questionnaire) in patients operated for 
carpal tunnel syndrome: n (%) 
Time points Gabapentin (n = 18) Control (n = 19) P*
Preoperative 18 (100) 19 (100) 1.000
2 weeks 6 (33.3) 8 (42.1) 0.737
1 month 5 (27.8) 8 (42.1) 0.495
3 months 5 (27.8) 7 (36.8) 0.728
6 months 4 (22.2) 5 (26.3) 1.000
DN4 (Douleur Neuropathique 4) questionnaire; *Fisher’s test.
Table 4. Complex regional pain syndrome according to the 
Budapest questionnaire among patients operated for carpal 
tunnel syndrome: n (%) 
Time points Gabapentin (n = 18) Control (n = 19) P*
2 weeks 5 (27.7) 9 (47.3) 0.231
1 month 6 (33.3) 10 (52.6) 0.131
3 months 4 (22.2) 6 (31.6) 0.535
6 months 3 (16.7) 3 (15.8) 0.944
*Student’s t test.
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pre or postoperative gabapentin dose after open-door nephrectomy, 
compared with placebo, but no difference between pre or postoper-
ative gabapentin. Further studies are still required, in order to better 
evaluate the effect of gabapentin on POCP prevention.25,26
The duration of the surgical procedure is known to have an 
impact on the development of POCP. Procedures that last longer 
than three hours have been correlated with an increased risk of 
POCP.27 However, the total duration of the surgical procedure in 
the current study was shorter than three hours, which may have 
contributed towards reduced incidence of POCP.
Brogly et al.17 demonstrated that there was lower incidence of 
POCP through using preoperative gabapentin prior to thyroidec-
tomy.17 The current report only assessed patients until six months 
of follow-up. However, evaluation after six months would most 
likely not find any differences in POCP, given that the pain inten-
sity was already mild in both groups at six months. 
Surgical procedures that may cause nerve injury have also 
been correlated with POCP.1 Previous studies have reported a 
wide range of POCP (5 to 80%), which may be related to different 
definitions in the various studies.28,29 Study design, POCP assess-
ment and interpretation of results may also contribute towards 
this variability.28
The incidence of POCP found in this report was higher than 
what was previously described.1 The observed incidence of POCP 
was 27.8% and 36.8% at three months, and 22.2% and 26.3% at 
six months, for G1 and G2, respectively, compared with 21% and 
12% at three and six months reported by Yung et al.1 One possible 
explanation might be the difference in surgical techniques: a lim-
ited open carpal tunnel release procedure was used in the above 
mentioned study. This could result in different efficacy, scar tissue 
compression of the median nerve and surgery-associated nerve 
injury, thus leading to POCP.1
IVRA is a simple anesthetic technique commonly used for 
carpal tunnel syndrome release. This type of surgery can usually 
be performed without intraoperative anesthetic supplementation 
because IVRA is sufficient for local anesthesia. As expected, there 
was no need for additional anesthesia in this study. Also, no seda-
tion was required since it is a fast procedure associated with low 
levels of patient distress.
However, its analgesic effect is limited to the duration of tour-
niquet use. Additional medication is usually necessary in order 
to maintain postoperative analgesia,2 and this was implemented 
through using paracetamol and codeine. The use of preoperative 
gabapentin did not affect postoperative analgesic consumption. 
Figure 1. Patients’ recruitment and allocation flowchart.
Assessed for eligibility (n = 60)
Enrollment
Randomized (n = 40)
Allocation
Excluded (n = 60)
Not meeting inclusion criteria (n = 20)
(2 due to arrhythmia, 4 due to myocardial
ischemia and 14 due to using opioids,
anticonvulsants or antidepressants)
Declined to participate (n = 0)
Allocated to intervention (n = 20)
Received allocated intervention (n = 20)
Allocated to placebo (n = 20)
Received allocated intervention (n = 20)
Follow-up
Lost from follow-up (without return) (n = 2) Lost from follow-up (without return) (n = 1)
Analysis
Analyzed (n = 18)
Excluded from analysis (without return) (n = 2)
Analyzed (n = 19)
Excluded from analysis (without return) (n = 1)
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Also, there was no difference in the reported side effects 
between the groups, as demonstrated by others.9,30 Common 
lidocaine-related side effects (e.g. metallic taste, oral paresthesia 
and tinnitus) were also not increased through using gabapentin.
LIMITATIONS OF THE STUDY
Gabapentin was given as a single preoperative dose, which may 
have been insufficient to reduce central sensitization and devel-
opment of POCP. Use of gabapentin and other neuromodulatory 
drugs was not allowed for treating POCP, which may have con-
tributed towards higher incidence of chronic pain. Additionally, 
this was a single-center study, which may limit the applicability 
of our results. 
CONCLUSION
In conclusion, there was no difference in postoperative pain 
intensity through using a single 600 mg gabapentin dose after 
open carpal tunnel release surgery.
Further studies are needed in order to determine the best 
perioperative gabapentin regimen for postoperative pain control 
and prevention of postoperative chronic pain syndrome after car-
pal tunnel surgery.
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